3 of the best ASX 200 stocks to buy in FY25

Big returns and buy ratings. That's what Bell Potter is saying about these shares.

| More on:
Four people gather around laptop and cheer

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new financial year is on the horizon, so what better time to make some new additions to your investment portfolio.

But which ASX 200 stocks could be buys?

Let's take a look at three best buys for FY 2025 according to analysts at Bell Potter. They are as follows:

Bega Cheese Ltd (ASX: BGA)

Bell Potter sees a lot of value in this diversified food company's shares. Particularly given that its outlook is becoming more positive and its shares are trading on historically low forward earnings multiples. It explains:

Our Buy rating remains on BGA is based on: (1) a historically low forward multiple; (2) consolidating milk processing infrastructure; and (3) the material valuation upside should BGA execute on its 5 year targets. In addition, we note that the key drivers of FY25e appear to have improved in recent months, with: (1) Australian milk production continuing to demonstrate YOY growth through 4Q24; (2) YOY gains in SMP pricing in FY25e futures markets; and (3) a material YOY downdraft in farmgate milk prices in FY25e based on minimum opens by major processors.

Bell Potter has a buy rating and $5.35 price target on its shares. This implies potential upside of 26% for investors over the next 12 months.

Neuren Pharmaceuticals Ltd (ASX: NEU)

Another ASX 200 stock that Bell Potter is bullish on for FY 2025 is biotechnology company Neuren Pharmaceuticals.

The broker believes it could be a great long term pick for patient investors. It explains:

In the last six months, NNZ-2591 reported highly encouraging Phase 2 data in two rare diseases. NEU will once again have first-to-market opportunities in these two rare diseases, assuming future Phase 3 trials are successful. While short-term news will continue to be impacted by Acadia's commercialisation of NEU's first drug, called Daybue, we maintain our BUY recommendation for investors who have a longer 2 to 3-year investment horizon.

Bell Potter has a buy rating and $28.00 price target on its shares. This suggests that potential upside of 32% is possible from current levels.

Boss Energy Ltd (ASX: BOE)

If you're not averse to investing in the mining sector, then this uranium miner could be an ASX 200 stock to buy according to Bell Potter.

The broker sees "significant value" in its shares right now. Especially given its geographically diversified multi-asset portfolio and the uranium bull market. It said:

BOE's Honeymoon project recommenced production in April-24, with first sales expected in July-24. The business over the last six months has changed somewhat, with the acquisition of a 30% interest in the Alta Mesa project with JV partner enCore energy in South Texas. We continue to see significant value in BOE, with optionality around expansion at Honeymoon via low-risk and cost regional resources at Jasons and Goulds Dam. With the inclusion of Alta Mesa, BOE boasts a geographically diversified multi-asset portfolio with several growth levers yet to be pulled, heading into a uranium bull market.

Bell Potter has a buy rating and $6.35 price target. This implies potential upside of 54% for investors.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Guess which beaten down ASX share is rocketing 11% today

Why are investors buying this beaten down stock? Let's find out.

Read more »

Broker working with share prices on computers.
Broker Notes

These 3 ASX All Ords stocks just got sizeable broker upgrades

Top brokers expect strong performance from these ASX All Ords stocks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Morgans says these ASX 200 stocks can rise 30%

Big returns could be on the cards for buyers of these shares.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A group of stockbrokers sit in a room with several computer screens in front of them as they discuss the Zip share price and Zip's merger with Sezzle
Broker Notes

Here are the latest broker rating changes on 3 prominent ASX shares

Brokers have delivered a mixed bag this week.

Read more »

Two people climb to the summit and raise their arms in success as the sun rises brightly over the mountains.
Financial Shares

'Strong momentum': 2 ASX financial shares backed by top fundie for 2025

ASX financial shares had a strong trading session on Tuesday with several new price records set.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Broker Notes

The best Australian shares to buy with $7,000 right now

Analysts think these shares could give you a good return on investment.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Broker Notes

Top broker says buy ResMed and this ASX 200 share

Ord Minnett was impressed with their quarterly updates from last month.

Read more »